Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma

QR Code

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma

Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (15 women, 24 men), median age 61 years (30–76 years...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. A. Belousov, T. A. Mitina, Yu. Yu. Chuksina, A. K. Golenkov, E. V. Kataeva, E. V. Trifonova, Yu. B. Chernykh, L. L. Vysotskaya, S. G. Zakharov, E. F. Klinushkina, A. N. Mitin
Format:	Article
Language:	Russian
Published:	ABV-press 2019-04-01
Series:	Онкогематология
Subjects:	multiple myeloma first-line therapy lenalidomide bortezomib polichemotherapy
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/331
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
by: M. Yu. Frolov, et al.
Published: (2017-08-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
by: Sara Bringhen, et al.
Published: (2025-07-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
by: Koki Tamai, et al.
Published: (2024-02-01)

Lenalidomide and its impact on exanthematous reactions: a case report
by: Cristiana Vieira-Maia, et al.
Published: (2025-04-01)

Bortezomib-based Chemotherapy and Bone-marrow Followed by Renal Transplantation in Multiple Myeloma: A Literature Review
by: Jasmine Sethi, et al.
Published: (2025-04-01)

Chemoresistance of PRAME-expressing melanoma cell can be resolved with help of bortezomib
by: V. A. Misyurin, et al.
Published: (2019-01-01)

Macrocusteio do uso do Bortezomibe no tratamento do Mieloma Múltiplo na perspectiva do SUS
by: Mariana Andrades Fiorini Monteiro Novo, et al.
Published: (2025-07-01)

Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects
by: E. Z. Irugova, et al.
Published: (2025-03-01)

Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)

Biological basis of immunomodulatory preparations using in treatment of multiple myeloma
by: S. V. Semochkin
Published: (2022-11-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Modern strategies in therapy of elderly patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review
by: Hongjuan Dong, et al.
Published: (2025-07-01)

The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia
by: Camila Terreros-Palacios, et al.
Published: (2025-07-01)

Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015-06-01)

Targeted Delivery of Bortezomib Using Retinoid-Based Nanoparticle: Modulating Liver Fibrosis through the TGF-β1/Smad3 Pathway
by: Samaneh Siapoush, et al.
Published: (2025-04-01)

FmocFF Peptide Hydrogel Is a Promising Matrix for Encapsulation and Controlled Release of the Anticancer Peptide Drug Bortezomib
by: Peter Divanach, et al.
Published: (2025-06-01)

Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model‐Informed Precision Dosing for Chinese Population With Renal Insufficiency
by: Yi Ma, et al.
Published: (2025-07-01)

Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01)

Bortezomib and quercetin as effective modulators of lipopolysaccharide-induced systemic inflammatory response and metabolic disorders
by: Ye. O. Morhun, et al.
Published: (2025-06-01)

The importance of preexisting drug resistance due to overexpression of P-glycoprotein for the formation of resistance to bortezomib
by: L. A. Laletina, et al.
Published: (2020-03-01)

The late extramedullary relapse of the multiple myeloma with a predominant lesion of the duodenum and pancreas (clinical observation and mini-review)
by: O. A. Rukavitsyn, et al.
Published: (2019-12-01)

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Moving Beyond G‐CSF Mobilization—Learning From a 15‐Year Experience of Different Stem Cell Mobilization Regimens in Multiple Myeloma
by: Sumeet Mirgh, et al.
Published: (2025-07-01)